ArticleJournal of nanobiotechnology2026
Ionic-bridge engineered α-lactalbumin nanoparticles integrated into electrospun nanofibers for controlled growth factor delivery and burn wound repair.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Protein-based nanoparticles hold great promise for bioactive molecule delivery, but conventional fabrication routes are often complex and rely on surfactants or organic solvents. Here, we reported a crosslinker-free strategy to engineer α-lactalbumin (ALA) nanoparticles via Ca²⁺ mediated ionic bridging and electrospraying, enabling efficient encapsulation of acidic fibroblast growth factor (aFGF). These aFGF@ALA nanoparticles were subsequently integrated into electrospun poly(vinyl alcohol) (PVA) nanofiber matrices to construct hybrid dressings (aFGF@ALA NPs/PVA ENMs). The resulting nanostructures combine the structural support of nanofibers with the controlled release capacity of protein nanoparticles, yielding a synergistic platform for therapeutic delivery. In vitro, the hybrid dressings promoted fibroblasts and keratinocytes proliferation and migration with excellent cytocompatibility. In vivo, they accelerated burn wound repair by enhancing re-epithelialization, collagen I/III remodeling, and angiogenesis. This work introduces a facile and generalizable strategy for designing functional protein-based nanoparticles and demonstrates their integration with nanofiber scaffolds as a versatile platform for growth factor delivery and tissue regeneration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.